网站首页
概要
The EasySep™ Release Human CD3 Positive Selection Kit is designed to isolate CD3+ cells from fresh or previously frozen peripheral blood mononuclear cells or washed leukapheresis samples by immunomagnetic positive selection.
Desired cells are labeled with antibodies and magnetic particles, and separated without columns using an EasySep™ magnet. Unwanted cells are simply poured off, while desired cells remain in the tube. Then, bound magnetic particles are removed from the EasySep™-isolated CD3+ cells, which are immediately available for downstream applications. Following cell isolation with this EasySep™ Release kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins or other chemically related ligands. The CD3 antigen is expressed on all T cells and CD56+ NKT cells.
This product is designed for cell therapy research applications following the recommendations of USP<1043> on Ancillary Materials, and we can currently work with you to qualify this reagent under an approved investigational new drug (IND) or clinical trial application (CTA).
This product aims to be developed as a cGMP-grade reagent for cellular therapy research. Learn more at www.stemcell.com/t-cell-therapy
Desired cells are labeled with antibodies and magnetic particles, and separated without columns using an EasySep™ magnet. Unwanted cells are simply poured off, while desired cells remain in the tube. Then, bound magnetic particles are removed from the EasySep™-isolated CD3+ cells, which are immediately available for downstream applications. Following cell isolation with this EasySep™ Release kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins or other chemically related ligands. The CD3 antigen is expressed on all T cells and CD56+ NKT cells.
This product is designed for cell therapy research applications following the recommendations of USP<1043> on Ancillary Materials, and we can currently work with you to qualify this reagent under an approved investigational new drug (IND) or clinical trial application (CTA).
This product aims to be developed as a cGMP-grade reagent for cellular therapy research. Learn more at www.stemcell.com/t-cell-therapy
技术资料
| Document Type | 产品名称 | Catalog # | Lot # | 语言 |
|---|---|---|---|---|
| Product Information Sheet | EasySep™ Release Human CD3 Positive Selection Kit | 17751 | All | English |
| Product Information Sheet | RoboSep™ Release Human CD3 Positive Selection Kit | 17751RF | All | English |
| Safety Data Sheet 1 | EasySep™ Release Human CD3 Positive Selection Kit | 17751 | All | English |
| Safety Data Sheet 2 | EasySep™ Release Human CD3 Positive Selection Kit | 17751 | All | English |
| Safety Data Sheet 3 | EasySep™ Release Human CD3 Positive Selection Kit | 17751 | All | English |
| Safety Data Sheet 1 | RoboSep™ Release Human CD3 Positive Selection Kit | 17751RF | All | English |
| Safety Data Sheet 2 | RoboSep™ Release Human CD3 Positive Selection Kit | 17751RF | All | English |
| Safety Data Sheet 3 | RoboSep™ Release Human CD3 Positive Selection Kit | 17751RF | All | English |
数据及文献
Data
Starting with a single-cell suspension of human PBMCs, the CD3+ cell content of the isolated fraction is typically 98.7 ± 0.9% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and final isolated fractions are 38.4% and 99.0%, respectively.
